Guardant Health Shares Surge as UnitedHealthcare Covers Shield Blood Test
UnitedHealthcare will begin reimbursing Guardant Health’s Shield colorectal cancer blood test from August 1, driving strong investor reaction and broader commercial access.
/ 352 items
#XY Event-Driven Stocks↓
Can-Fite’s Namodenoson Shows Promising Survival Signals in Advanced Pancreatic Cancer Phase 2a Study
Can-Fite’s Namodenoson met safety endpoint and showed encouraging survival signals in Phase 2a pancreatic cancer study, including median OS >5 months in third-line patients and one survivor over 18 months.
Sarepta Moves Closer to Full Approval for Two Key Duchenne Muscular Dystrophy Drugs
Sarepta DMD drugs AMONDYS 45 and VYONDYS 53 near full FDA approval; decision due Feb 2027.
Nuvectis Pharma Shares Plunge After Pricing $100 Million Stock Offering
The stock had nearly tripled this month before the dilution announcement.
Vistagen Crashes as Fasedienol Phase 3 Trial Misses Primary Endpoint
The company plans further FDA discussions and a strategic pivot to longer-term treatment.
Unicycive Therapeutics Receives FDA Complete Response Letter for Resubmitted OLC NDA
The CRL relates to third-party manufacturing issues, but the FDA raised no concerns about clinical efficacy or safety.